Vademecum

PACLITAXEL

http://www.rxlist.com/cgi/generic/paclitaxel_ad.htm

CLINICAL PHARMACOLOGY Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Following intravenous administration of TAXOL, paclitaxel plasma concentrations declined in a biphasic manner. The initial rapid decline represents distribution to the peripheral compartment and elimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from the peripheral compartment. Pharmacokinetic parameters of paclitaxel following 3-and 24-hour infusions of TAXOL at dose levels of 135 and 175 mg/m2 were determined in a Phase 3 randomized study in ovarian cancer patients and are summarized in the following table: Summary of Pharmacokinetic Parameters - Mean Values Dose (mg/m2) Infusion Duration (h) N (patients) Cmax (ng/mL) AUC (0-ï¿½ ) (ngï¿½h/mL) T-HALF (h) CLT (L/h/m2) 135 24 2 195 6300 52.7 21.7 175 24 4 365 7993 15.7 23.8 135 3 7 2170 7952 13.1 17.7 175 3 5 3650 15007 20.2 12.2 Cmax= Maximum plasma concentration AUC (0-ï¿½ )=Area under the plasma concentration-time curve from time 0 to infinity CLT = Total body clearance It appeared that with the 24-hour infusion of TAXOL, a 30% increase in dose (135 mg/m2 versus 175 mg/m2 ) increased the Cmax by 87%, whereas the AUC (0-ï¿½) remained proportional. However, with a 3-hour infusion, for a 30% increase in dose, the Cmax and AUC (0-ï¿½) were increased by 68% and 89%, respectively. The mean apparent volume of distribution at steady state, with the 24-hour infusion of TAXOL, ranged from 227 to 688 L/m2 , indicating extensive extravascular distribution and/or tissue binding of paclitaxel. The pharmacokinetics of paclitaxel were also evaluated in adult cancer patients who received single doses of 15-135 mg/m2 given by 1-hour infusions (n=15), 30-275 mg/m2 given by 6-hour infusions (n=36), and 200-275 mg/m2 given by 24-hour infusions (n=54) in Phase 1 & 2 studies. Values for CLT and volume of distribution were consistent with the findings in the Phase 3 study. The pharmacokinetics of TAXOL in patients with AIDS-related Kaposiï¿½s sarcoma have not been studied. In vitro studies of binding to human serum proteins, using paclitaxel concentrations ranging from 0.1 to 50 mcg/mL, indicate that between 89-98% of drug is bound; the presence of cimetidine, ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel. After intravenous administration of 15-275 mg/m2 doses of TAXOL as 1-, 6-, or 24-hour infusions, mean values for cumulative urinary recovery of unchanged drug ranged from 1.3 to 12.6% of the dose, indicating extensive non-renal clearance. In five patients administered a 225 or 250 mg/m2 dose of radiolabeled TAXOL as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine. Total recovery of radioactivity ranged from 56 to 101% of the dose. Paclitaxel represented a mean of 5% of the administered radioactivity recovered in the feces, while metabolites, primarily 6a-hydroxypaclitaxel, accounted for the balance. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydroxypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3ï¿½-p-hydroxypaclitaxel and 6a, 3ï¿½-p-dihydroxypaclitaxel, by CYP3A4. In vitro, the metabolism of paclitaxel to 6a- hydroxypaclitaxel was inhibited by a number of agents (ketoconazole, verapamil, diazepam, quinidine, dexamethasone, cyclosporin, teniposide, etoposide, and vincristine), but the concentrations used exceeded those found in vivo following normal therapeutic doses. Testosterone, 17a-ethinyl estradiol, retinoic acid, and quercetin, a specific inhibitor of CYP2C8, also inhibited the formation of 6a-hydroxypaclitaxel in vitro. The pharmacokinetics of paclitaxel may also be altered in vivoas a result of interactions with compounds that are substrates, inducers, or inhibitors of CYP2C8 and or CYP3A4. (See DRUG INTERACTIONS section.) The effect of renal or hepatic dysfunction on the disposition of paclitaxel has not been investigated. Possible interactions of paclitaxel with concomitantly administered medications not been formally investigated. CLINICAL STUDIES Ovarian Carcinoma: Data from five Phase 1 and 2 clinical studies (189 patients), a multicenter, randomized Phase 3 study (407 patients), as well as an interim analysis of data from more than 300 patients enrolled in a treatment referral center program were used in support of the use of TAXOL (paclitaxel) Injection in patients who have failed initial or subsequent chemotherapy for metastatic carcinoma of the ovary. Two of the Phase 2 studies (92 patients) utilized an initial dose of 135 to 170 mg/m2 in most patients ( >90%) administered over 24 hours by continuous infusion. Response rates in these two studies were 22% (95% CI = 11-37%) and 30% (95% CI = 18-46%) with a total of six complete and 18 partial responses in 92 patients. The median duration of overall response in these two studies measured from the first day of treatment was 7.2 months (range: 3.5-15.8 months) and 7.5 months (range: 5.3-17.4 months), respectively. The median survival was 8.1 months (range: 0.2-36.7 months) and 15.9 months (range: 1.8- 34.5+ months). Phase 3 study had a bifactorial design and compared the efficacy and safety of TAXOL, administered at two different doses (135 or 175 mg/m2 ) and schedules (3- or 24-hour infusion). The overall response rate for the 407 patients was 16.2% (95%CI=12.8- 20.2%),with 6 complete and 60partial responses. Duration of response, measured from the first day of treatment was 8.3 months (range: 3.2-21.6 months). Median time to progression was 3.7 months (range: 0.1+ -25.1+ months). Median survival was 11.5 months (range: 0.2- 26.3+ months). Response rates, median survival and median time to progression for the 4 arms are given in the following table. Efficacy in the Phase 3 Ovarian Carcinoma Study 175/3 175/24 135/3 135/24 (n=96) (n=106) (n=99) (n=106) ï¿½Response - rate (percent) 14.6 21.7 15.2 13.2 - 95% Confidence Interval (8.5-23.6) (14.5-31.0) (9.0-24.1) (7.7-21.5) ï¿½Time to Progression - median (months) 4.4 4.2 3.4 2.8 - 95% Confidence Interval (3.0-5.6) (3.5-5.1) (2.8-4.2) (1.9-4.0) ï¿½Survival - median (months) 11.5 11.8 13.1 10.7 - 95% Confidence Interval (8.4-14.4) (8.9-14.6) (9.1-14.6) (8.1-13.6) Analyses were performed as planned by the study protocol, by comparing the two doses (135 or 175 mg/m2 ) irrespective of the schedule (3 or 24 hours) and the two schedules irrespective of dose. Patients receiving the 175 mg/m2 dose achieved a higher response rate than those receiving the 135 mg/m2 dose: 18 vs. 14% (p= 0.28). No difference in response rate was detected when comparing the 3-hour with the 24-hour infusion: 15 vs. 17% (p= 0.50). Patients receiving the 175 mg/m2 dose of TAXOL had a longer time to progression than those receiving the 135 mg/m2 dose: median 4.2 vs. 3.1 months (p= 0.03). Time to progression was longer for patients receiving the 3-hour vs. the 24-hour infusion: 4.0 months vs. 3.7 months (p= 0.08). No difference in survival according to dose or schedule was observed. These statistical analyses should be viewed with caution because of the multiple comparisons made. TAXOL remained active in patients who had developed resistance to platinum-containing therapy (defined as tumor progression while on, or tumor relapse within 6 months from completion of, a platinum-containing regimen) with response rates of 14% in the Phase 3 study and 31% in the Phase 1 & 2 clinical studies. The adverse event profile in the Phase 3 study was consistent with that seen for a pooled analysis performed on 812 patients treated in ten clinical studies (see ADVERSE REACTIONS section). For the 403 patients who received TAXOL in the Phase 3 study, the following table shows the incidence of several important adverse events. Frequency* of Important Adverse Events in the Phase 3 Ovarian Carcinoma Study Percent of Patients 175/3 175/24 135/3 135/24 (n=95) (n=105) (n=98) (n=105) ï¿½ Bone Marrow - Neutropenia <2,000/mm3 78 98 78 98 <500/mm3 27 75 14 67 - Thrombocytopenia <100,000/mm3 4 18 8 6 <50,000/mm3 1 7 2 1 - Anemia <11g/dL 84 90 68 88 <8 g/dL 11 12 6 10 - Infections 26 29 20 18 ï¿½ Hypersensitivity Reaction** - All 41 45 38 45 - Severe 2 0 2 1 ï¿½ Peripheral Neuropathy - Any symptoms 63 60 55 42 - Severe symptoms 1 2 0 0 ï¿½ Mucositis - Any symptoms 17 35 21 25 - Severe symptoms 0 3 0 2 * Based on worst course analysis ** All patients received premedication Myelosuppression was dose and schedule related, with the schedule effect being more prominent. The development of severe hypersensitivity reactions (HSRs) was rare; 1% of the patients and 0.2% of the courses overall. There was no apparent dose or schedule effect seen for the HSRs. Peripheral neuropathy was clearly dose-related, but schedule did not appear to affect the incidence. The results of the randomized study support the use of TAXOL at doses of 135 or 175 mg/m2 , administered by a 3-hour intravenous infusion. The same doses administered by 24-hour infusion were more toxic. Breast Carcinoma: Data from 83 patients accrued in three phase 2 open label studies and from 471 patients enrolled in a phase 3 randomized study were available to support the use of TAXOL in patients with metastatic breast carcinoma. The Phase 2 open label studies - Two studies were conducted in 53 patients previously treated with a maximum of one prior chemotherapeutic regimen. TAXOL was administered in these 2 trials as a 24-hour infusion at initial doses of 250 mg/m2 (with G-CSF support) or 200 mg/m2 . The response rates were 57% (95% CI: 37-75%) and 52% (95% CI: 32-72%), respectively. The third phase 2 study was conducted in extensively pretreated patients who had failed anthracycline therapy and who had received a minimum of 2 chemotherapy regimens for the treatment of metastatic disease. The dose of TAXOL was 200 mg/m2 as a 24-hour infusion with G-CSF support. Nine of the 30 patients achieved a partial response, for a response rate of 30% (95% CI: 15- 50%). The Phase 3 randomized study - This multicenter trial was conducted in patients previously treated with one or two regimens of chemotherapy. Patients were randomized to receive TAXOL at a dose of either 175 mg/m2 or 135 mg/m2 given as a 3-hour infusion. In the 471 patients enrolled, 60% had symptomatic disease with impaired performance status at study entry, and 73% had visceral metastases. These patients had failed prior chemotherapy either in the adjuvant setting (30%), the metastatic setting (39%), or both (31%). Sixty-seven percent of the patients had been previously exposed to anthracyclines and 23% of them had disease considered resistant to this class of agents. The overall response rate for the 454 evaluable patients was 26% (95% CI: 22-30%), with 17 complete and 99 partial responses. The median duration of response, measured from the first day of treatment, was 8.1 months (range: 3.4- 18.1+ months). Overall for the 471 patients, the median time to progression was 3.5 months (range: 0.03-17.1 months). Median survival was 11.7 months (range: 0-18.9 months). Response rates, median survival and median time to progression for the 2 arms are given in the following table. Efficacy in the Phase 3 Breast Carcinoma Study 175/ 3 135/ 3 (n=235) (n=236) ï¿½ Response - rate (percent) 28 22 - 95% Confidence Interval (22-34) (17-27) ï¿½ Time to Progression - median (months) 4.2 3.0 - 95% Confidence Interval (3.2-4.6) (2.5-3.8) ï¿½ Survival - median (months) 11.7 10.5 - 95% Confidence Interval (10.0-13.8) (9.0-12.8) For the 458 patients who received TAXOL (paclitaxel) Injection in the Phase 3 study, the following table shows the incidence of several important adverse events by treatment arm (each arm was administered by a 3-hour infusion). Frequency* of Important Adverse Events in the Phase 3 Breast Carcinoma Study Percent of Patients 175 mg/m2 135 mg/m2 (n=229) (n=229) ï¿½ Bone Marrow - Neutropenia <2,000/mm3 90 81 <500/mm3 28 19 - Thrombocytopenia <100,000/mm3 11 7 <50,000/mm3 3 2 - Anemia < 11 g/dL 55 47 < 8 g/dL 4 2 - Infections 23 15 - Febrile Neutropenia 2 2 ï¿½ Hypersensitivity Reaction** - All 36 31 - Severe 0 <1 ï¿½ Peripheral Neuropathy - Any symptoms 70 46 - Severe symptoms 7 3 ï¿½ Mucositis - Any symptoms 23 17 - Severe symptoms 3 <1 * Based on worst course analysis ** All patients received premedication Myelosuppression and peripheral neuropathy were dose related. There was one severe hypersensitivity reaction (HSR) observed at the dose of 135 mg/m2 . AIDS-Related Kaposiï¿½s Sarcoma: Data from two Phase 2 open label studies support the use of TAXOL as second-line therapy in patients with AIDS related Kaposiï¿½s sarcoma. Fifty-nine of the 85 patients enrolled in these studies had previously received systemic therapy, including interferon alpha (32%), DaunoXomeï¿½ (31%), DOXILï¿½ (2%) and doxorubicin containing chemotherapy (42%), with 64% having received prior anthracyclines. Eightyfive percent of the pretreated patients had progressed on, or could not tolerate, prior systemic therapy. In Study CA139-174 patients received TAXOL at 135 mg/m2 as a 3-hour infusion every 3 weeks (intended dose intensity 45 mg/m2/week). If no dose limiting toxicity was observed, patients were to receive 155 mg/m2 and 175 mg/m2 in subsequent courses. Hematopoietic growth factors were not to be used initially. In Study CA139-281 patients received TAXOL at 100 mg/m2 as a 3-hour infusion every 2 weeks (intended dose intensity 50 mg/m2/week). In this study patients could be receiving hematopoietic growth factors before the start of TAXOL therapy, or this support was to be initiated as indicated; the dose of TAXOL was not increased. The dose intensity of TAXOL used in this patient population was lower than the dose intensity recommended for other solid tumors. All patients had widespread and p.o. risk disease. Applying the ACTG staging criteria to patients with prior systemic therapy, 93% were poor risk for extent of disease (T1), 88% had a CD4 count <200 cells/mm3 (I1), and 97% had p.o. risk considering their systemic illness (S1). All patients in Study CA139-174 had a Karnofsky performance status of 80 or 90 at baseline; in Study CA139-281, there were 26 (46%) patients with a Karnofsky performance status of 70 or worse at baseline. Extent of Disease at Study Entry Percent of Patients Prior Systemic Therapy (n=59) Visceral ï¿½ edema ï¿½ oral ï¿½ cutaneous 42 Edema or lymph nodes ï¿½ oral cutaneous 41 oral ï¿½ cutaneous 10 Cutaneous only 7 Although the planned dose intensity in the two studies was slightly different (45 mg/m2/week in Study CA139-174 and 50 mg/m2 /week in Study CA139-281), delivered dose intensity was 38-39 mg/m2/week in both studies, with a similar range (20-24 to 51-61). Efficacy - The efficacy of TAXOL was evaluated by assessing cutaneous tumor response according to the amended ACTG criteria and by seeking evidence of clinical benefit in patients in six domains of symptoms and/or conditions that are commonly related to AIDS-related Kaposiï¿½s sarcoma. Cutaneous Tumor Response (Amended ACTG Criteria) - The objective response rate was 59% (95% CI: 46 to 72%)( 35 of 59 patients) in patients with prior systemic therapy. Cutaneous responses were primarily defined as flattening of more than 50% of previously raised lesions. Overall Best Response (Amended ACTG Criteria) Percent of Patients Prior Systemic Therapy (n=59) Complete response 3 Partial response 56 Stable disease 29 Progression 8 Early death/toxicity 3 The median time to response was 8.1 weeks and the median duration of response measured from the first day of treatment was 10.4 months (95% CI: 7.0 to 11.0 months) for the patients who had previously received systemic therapy. The median time to progression was 6.2 months (95% CI: 4.6 to 8.7 months). Additional Clinical Benefit - Most data on patient benefit were assessed retrospectively (plans for such analyses were not included in the study protocols). Nonetheless, clinical descriptions and photographs indicated clear benefit in some patients, including instances of improved pulmonary function in patients with pulmonary involvement, improved ambulation, resolution of ulcers, and decreased analgesic requirements in patients with KS involving the feet and resolution of facial lesions and edema in patients with KS involving the face, extremities and genitalia. Safety- The adverse event profile of TAXOL (paclitaxel) Injection administered to patients with advanced HIV disease and poor-risk AIDS-related Kaposiï¿½s sarcoma was generally similar to that seen in a pooled analysis of 812 patients with solid tumors (see ADVERSE REACTIONS section). In this immunosuppressed patient population, however, a lower dose intensity of TAXOL and supportive therapy including hematopoietic growth factors in patients with severe neutropenia are recommended. Patients with AIDS-related Kaposiï¿½s sarcoma may have more severe hematologic toxicities than patients with solid tumors.

SIDE EFFECTS

Data in the following table are based on the experience of 812 patients (493 with ovarian carcinoma and 319 with breast carcinoma) enrolled in 10 studies. Two hundred and seventy-five patients were treated in 8 Phase 2 studies with TAXOL doses ranging from 135 to 300 mg/m2 administered over 24 hours (in 4 of these studies, G-CSF was administered as hematopoietic support). Three hundred and one patients were treated in the randomized Phase 3 ovarian carcinoma study which compared two doses (135 or 175 mg/m2) and two schedules (3 or 24 hours) of TAXOL. Two hundred and thirty-six patients with breast carcinoma received TAXOL (135 or 175 mg/m2) administered over 3 hours in a controlled study. Summary of Adverse Events in 812 Patients With Solid Tumors Receiving Single-Agent TAXOL % Incidence ï¿½ Bone Marrow - Neutropenia < 2,000/mm3 90 < 500/mm3 52 - Leukopenia < 4,000/mm3 90 < 1,000/mm3 17 - Thrombocytopenia < 100,000/mm3 20 < 50,000/mm3 7 - Anemia < 11 g/dL 78 < 8 g/dL 16 - Infections 30 - Bleeding 14 - Red Cell Transfusions 25 - Platelet Transfusions 2 ï¿½ Hypersensitivity Reaction1 - All 41 - Severe 2 ï¿½ Cardiovascular - Vital Sign Changes2 --- Bradycardia (N=537) 3 --- Hypotension (N=532) 12 - Significant Cardiovascular Events 1 ï¿½ Abnormal ECG - All Pts 23 - Pts with normal baseline (N=559) 14 ï¿½ Peripheral Neuropathy - Any symptoms 60 - Severe symptoms 3 ï¿½ Myalgia/ Arthralgia - Any symptoms 60 - Severe symptoms 8 ï¿½ Gastrointestinal - Nausea and vomiting 52 - Diarrhea 38 - Mucositis 31 ï¿½ Alopecia 87 ï¿½ Hepatic (Pts with normal baseline and on study data) - Bilirubin elevations (N=765) 7 - Alkaline phosphatase elevations (N=575) 22 - AST (SGOT) elevations (N=591) 19 ï¿½ Injection Site Reaction 13 1 All patients received premedication 2 During the first 3- hours of infusion None of the observed toxicities were clearly influenced by age. The following table shows the frequency of important adverse events in the 85 patients with KS treated with two different TAXOL (paclitaxel) Injection regimens. Frequency* of Important Adverse Events in the AIDS- Related Kaposiï¿½s Sarcoma Studies Percent of Patients Study CA139-174 Study CA139-281 135 mg/m2q 3 wk 100 mg/m2 q 2 wk (n=29) (n=56) ï¿½ Bone Marrow - Neutropenia < 2,000/mm3 100 95 < 500/mm3 76 35 - Thrombocytopenia < 100,000/mm3 52 27 < 50,000/mm3 17 5 - Anemia < 11 g/dL 86 73 < 8 g/dL 34 25 - Febrile Neutropenia 55 9 ï¿½ Opportunistic Infection - Any 76 54 - Cytomegalovirus 45 27 - Herpes Simplex 38 11 - Pneumocystis carinii 14 21 - M. avium intracellulare 24 4 - Candidiasis, esophageal 7 9 - Cryptosporidiosis 7 7 - Cryptococcal meningitis 3 2 - Leukoencephalopathy ï¿½ 2 ï¿½ Hypersensitivity Reaction** - All 14 9 ï¿½ Cardiovascular - Hypotension 17 9 - Bradycardia 3 ï¿½ ï¿½ Peripheral Neuropathy - Any 79 46 - Severe 10 2 ï¿½ Myalgia/ Arthralgia - Any 93 48 - Severe 14 16 ï¿½ Gastrointestinal - Nausea and Vomiting 69 70 - Diarrhea 90 73 - Mucositis 45 20 ï¿½ Renal (creatinine elevation) - Any 34 18 - Severe (grade III/ IV) 7 5 ï¿½ Discontinuation for drug toxicity 7 16 * Based on worst course analysis ** All patients received premedication As demonstrated in this table, toxicity was more pronounced in the study utilizing TAXOL at a dose of 135 mg/m2 every 3 weeks than in the study utilizing TAXOL at a dose of 100 mg/m2 every 2 weeks. Notably, severe neutropenia (76% versus 35%), febrile neutropenia (55% versus 9%), and opportunistic infections (76% versus 54%) were more common with the former dose and schedule. The differences between the two studies with respect to dose escalation and use of hematopoietic growth factors, as described above, should be taken into account. (See CLINICAL PHARMACOLOGY, CLINICAL STUDIES: AIDS-Related Kaposiï¿½s Sarcoma section.) Note also that only 26% of the 85 patients in these studies received concomitant treatment with protease inhibitors, whose effect on paclitaxel metabolism has not yet been studied. The following discussion refers to the overall safety database of 812 patients with solid tumors treated in clinical studies. The frequency and severity of adverse events have been generally similar for patients receiving TAXOL for the treatment of ovarian or breast carcinoma or for Kaposiï¿½s sarcoma, but patients with AIDS-related Kaposiï¿½s sarcoma may have more frequent and severe hematologic toxicity, infections, and febrile neutropenia. These patients require a lower dose intensity and supportive care. (See CLINICAL PHARMACOLOGY, CLINICAL STUDIES: AIDS-Related Kaposiï¿½s Sarcoma section.) In addition, rare events have been reported from the postmarketing experience or from other clinical studies; toxicities that were observed only in the population with Kaposiï¿½s sarcoma or that occurred with greater severity in this population are also described. The frequency and severity of important adverse events for the Phase 3 ovarian and breast carcinoma studies are presented in tabular form by treatment arm in the CLINICAL PHARMACOLOGY - CLINICAL STUDIES section. Hematologic: Bone marrow suppression was the major dose-limiting toxicity of TAXOL. Neutropenia, the most important hematologic toxicity, was dose and schedule dependent and was generally rapidly reversible. Among patients treated in the Phase 3 ovarian study with a 3-hour infusion, neutrophil counts declined below 500 cells/mm3 in 13% of the patients treated with a dose of 135 mg/m2 compared to 27% at a dose of 175 mg/m2 (p= 0.05). In the same study, severe neutropenia (<500 cells/mm3) was more frequent with the 24-hour than with the 3-hour infusion; infusion duration had a greater impact on myelosuppression than dose. Neutropenia did not appear to increase with cumulative exposure and did not appear to be more frequent nor more severe for patients previously treated with radiation therapy. Fever was frequent (12% of all treatment courses). Infectious episodes occurred in 30% of all patients and 9% of all courses; these episodes were fatal in 1% of all patients, and included sepsis, pneumonia and peritonitis. In the Phase 3 ovarian study, infectious episodes were reported in 19% of the patients given either 135 or 175 mg/m2 dose by a 3-hour infusion. Urinary tract infections and upper respiratory tract infections were the most frequently reported infectious complications. In the immunosuppressed patient population with advanced HIV disease and poor-risk AIDS-related Kaposiï¿½s sarcoma, 61% of the patients reported at least one opportunistic infection. (See CLINICAL PHARMACOLOGY, CLINICAL STUDIES: AIDS- Related Kaposiï¿½s Sarcoma section.) The use of supportive therapy, including G-CSF, is recommended for patients who have experienced severe neutropenia. (See DOSAGE AND ADMINISTRATION section.) Thrombocytopenia was uncommon, and almost never severe (< 50,000 cells/mm3 ). Twenty percent of the patients experienced a drop in their platelet count below 100,000 cells/mm3 at least once while on treatment; 7% had a platelet count <50,000 cells/mm3 at the time of their worst nadir. Among the 812 patients, bleeding episodes were reported in 4% of all courses and by 14% of all patients but most of the hemorrhagic episodes were localized and the frequency of these events was unrelated to the TAXOL dose and schedule. In the Phase 3 ovarian study, bleeding episodes were reported in 10% of the patients receiving either the135 or 175 mg/m2 dose given by a 3-hour infusion; no patients treated with the 3-hour infusion received platelet transfusions. Anemia (Hb <11 g/dL) was observed in 78% of all patients and was severe (Hb <8 g/dL) in 16% of the cases. No consistent relationship between dose or schedule and the frequency of anemia was observed. Among all patients with normal baseline hemoglobin, 69% became anemic on study but only 7% had severe anemia. Red cell transfusions were required in 25% of all patients and in 12% of those with normal baseline hemoglobin levels. Hypersensitivity Reactions (HSRs): All patients received premedication prior to TAXOL (see WARNINGS and PRECAUTIONS: Hypersensitivity REACTIONSsections). The frequency and severity of HSRs were not affected by the dose or schedule of TAXOL (paclitaxel) Injection administration. In the Phase 3 ovarian study the 3-hour infusion was not associated with a greater increase in HSRs when compared to the 24-hour infusion. Hypersensitivity reactions were observed in 20% of all courses and in 41% of all patients. These reactions were severe in less than 2% of the patients and 1% of the courses. No severe reactions were observed after course 3 and severe symptoms occurred generally within the first hour of TAXOL infusion. The most frequent symptoms observed during these severe reactions were dyspnea, flushing, chest pain and tachycardia. The minor hypersensitivity reactions consisted mostly of flushing (28%), rash (12%), hypotension (4%), dyspnea (2%), tachycardia (2%) and hypertension (1%). The frequency of hypersensitivity reactions remained relatively stable during the entire treatment period. Rare reports of chills and reports of back pain in association with hypersensitivity reactions have been received as proof of the continuing surveillance of TAXOL safety. Cardiovascular: Hypotension, during the first 3 hours of infusion, occurred in 12% of all patients and 3% of all courses administered. Bradycardia, during the first 3 hours of infusion, occurred in 3% of all patients and 1% of all courses. In the Phase 3 ovarian study, neither dose nor schedule had an effect on the frequency of hypotension and bradycardia. These vital sign changes most often caused no symptoms and required neither specific therapy nor treatment discontinuation. The frequency of hypotension and bradycardia were not influenced by prior anthracycline therapy. Significant cardiovascular events possibly related to TAXOL occurred in approximately 1% of all patients. These events included syncope, rhythm abnormalities, hypertension and venous thrombosis. One of the patients with syncope treated with TAXOL at 175 mg/m2 over 24 hours had progressive hypotension and died. The arrhythmias included asymptomatic ventricular tachycardia, bigeminy and complete AV block requiring pacemaker placement. Electrocardiogram (ECG) abnormalities were common among patients at baseline. ECG abnormalities on study did not usually result in symptoms, were not dose-limiting, and required no intervention. ECG abnormalities were noted in 23% of all patients. Among patients with a normal ECG prior to study entry, 14% of all patients developed an abnormal tracing while on study. The most frequently reported ECG modifications were non-specific repolarization abnormalities, sinus bradycardia, sinus tachycardia and premature beats. Among patients with normal ECGs at baseline, prior therapy with anthracyclines did not influence the frequency of ECG abnormalities. Cases of myocardial infarction have been reported rarely. Congestive heart failure has been reported typically in patients who have received other chemotherapy, notably anthracyclines. (See DRUG INTERACTIONS section.) Rare reports of atrial fibrillation and supraventricular tachycardia have been received as proof of the continuing surveillance of TAXOL safety. Respiratory: Rare reports of interstitial pneumonia, lung fibrosis and pulmonary embolism have been received as proof of the continuing surveillance of TAXOL safety. Rare reports of radiation pneumonitis have been received in patients receiving concurrent radiotherapy. Neurologic: The frequency and severity of neurologic manifestations were dose-dependent, but were not influenced by infusion duration. Peripheral neuropathy was observed in 60% of all patients (3% severe) and in 52% (2% severe) of the patients without pre-existing neuropathy. The frequency of peripheral neuropathy increased with cumulative dose. Neurologic symptoms were observed in 27% of the patients after the first course of treatment and in 34-51% from course 2 to 10. Peripheral neuropathy was the cause of TAXOL discontinuation in 1% of all patients. Sensory symptoms have usually improved or resolved within several months of TAXOL discontinuation. The incidence of neurologic symptoms did not increase in the subset of patients previously treated with cisplatin. Pre-existing neuropathies resulting from prior therapies are not a contraindication for TAXOL therapy. Other than peripheral neuropathy, serious neurologic events following TAXOL administration have been rare (< 1%) and have included grand mal seizures, syncope, ataxia and neuroencephalopathy. Rare reports of autonomic neuropathy resulting in paralytic ileus have been received as proof of the continuing surveillance of TAXOL safety. Optic nerve and or visual disturbances (scintillating scotomata) have also been reported, particularly in patients who have received higher doses than those recommended. These effects generally have been reversible. However, rare reports in the literature of abnormal visual evoked potentials in patients have suggested persistent optic nerve damage. Arthralgia/ Myalgia: There was no consistent relationship between dose or schedule of TAXOL and the frequency or severity of arthralgia/ myalgia. Sixty percent of all patients treated experienced arthralgia/myalgia; 8% experienced severe symptoms. The symptoms were usually transient, occurred two or three days after TAXOL administration, and resolved within a few days. The frequency and severity of musculoskeletal symptoms remained unchanged throughout the treatment period. Hepatic: No relationship was observed between liver function abnormalities and either dose or schedule of TAXOL administration. Among patients with normal baseline liver function 7%, 22% and 19% had elevations in bilirubin, alkaline phosphatase and AST (SGOT), respectively. Prolonged exposure to TAXOL was not associated with cumulative hepatic toxicity. Rare reports of hepatic necrosis and hepatic encephalopathy leading to death have been received as proof of the continuing surveillance of TAXOL safety. Renal: Among the patients treated for Kaposiï¿½s sarcoma with TAXOL, five patients had renal toxicity of grade III or IV severity. One patient with suspected HIV nephropathy of grade IV severity had to discontinue therapy. The other four patients had renal insufficiency with reversible elevations of serum creatinine. Gastrointestinal (GI): Nausea/ vomiting, diarrhea and mucositis were reported by 52%, 38% and 31% of all patients, respectively. These manifestations were usually mild to moderate. Mucositis was schedule dependent and occurred more frequently with the 24-hour than with the 3-hour infusion. In patients with poor-risk AIDS-related Kaposiï¿½s sarcoma, nausea/vomiting, diarrhea, and mucositis were reported by 69%, 79%, and 28% of patients, respectively. One third of patients with Kaposiï¿½s sarcoma complained of diarrhea prior to study start. (See CLINICAL PHARMACOLOGY, CLINICAL STUDIES: AIDS- Related Kaposiï¿½s Sarcoma section.) Rare reports of intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, and dehydration have been received as proof of the continuing surveillance of TAXOL safety. Rare reports of neutropenic enterocolitis (typhlitis), despite the coadministration of G-CSF, were observed in patients treated with TAXOL alone and in combination with other chemotherapeutic agents. Injection Site Reaction: Injection site reactions, including reactions secondary to extravasation, were usually mild and consisted of erythema, tenderness, skin discoloration, or swelling at the injection site. These reactions have been observed more frequently with the 24-hour infusion than with the 3-hour infusion. Recurrence of skin reactions at a site of previous extravasation following administration of TAXOL at a different site, i.e., "recall", has been reported rarely. Rare reports of more severe events such as phlebitis, cellulitis, induration, skin exfoliation, necrosis and fibrosis have been received as proof of the continuing surveillance of TAXOL safety. In some cases the onset of the injection site reaction either occurred during a prolonged infusion or was delayed by a week to ten days. A specific treatment for extravasation reactions is unknown at this time. Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration. Other Clinical Events: Alopecia was observed in almost all (87%) of the patients. Transient skin changes due to TAXOL- related hypersensitivity reactions have been observed, but no other skin toxicities were significantly associated with TAXOL (paclitaxel) Injection administration. Nail changes (changes in pigmentation or discoloration of nail body were uncommon (2%). Edema was reported in 21% of all patients (17% of those without baseline edema); only 1% had severe edema and none of these patients required treatment discontinuation. Edema was most commonly focal and disease-related. Edema was observed in 5% of all courses for patients with normal baseline and did not increase with time on study. Rare reports of skin abnormalities related to radiation recall as well as reports of maculopapular rash and pruritus have been received as part of the continuing surveillance of TAXOL safety. Reports of asthenia and malaise have been received as proof of the continuing surveillance of TAXOL safety. Accidental Exposure: Upon inhalation, dyspnea, chest pain, burning eyes, sore throat and nausea have been reported. Following topical exposure, events have included tingling, burning and redness.

DRUG INTERACTIONS In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2 ) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (i.e., TAXOL before cisplatin). Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when TAXOL was administered following cisplatin. The metabolism of TAXOL is catalyzed by cytochrome P450 isoenzymes CYP2C8 and CYP3A4. In the absence of formal clinical drug interaction studies, caution should be exercised when administering TAXOL concomitantly with known substrates or inhibitors of the cytochrome P450 isoenzymes CYP2C8 and CYP3A4. (See CLINICAL PHARMACOLOGY section.) Potential interactions between paclitaxel, a substrate of C.P.A. and protease inhibitors (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of C.P.A. have not been evaluated in clinical trials. Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when paclitaxel and doxorubicin are used in combination.